CliffBio
small molecule

BUDESONIDE

BUDESONIDE

Loss of exclusivity—loss of exclusivity
CompanyCipla →See this company's full patent-cliff portfolio

Drug detail

Brand nameBUDESONIDE
Active ingredientBUDESONIDE
Strength0.25MG/2ML
Dosage formSUSPENSION
RouteINHALATION
ModalitySmall molecule
FDA approvalNovember 2017
Marketing statusRX

More from Cipla

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

BUDESONIDE patent cliff — loss of exclusivity — | CliffBio